Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArcticZymes Technologies ASALTS:0DRV 74 EV-to-EBIT is 67.03 as of Aug. 19, 2026, which is 27% above its 10-year median of 52.64. GuruFocus rates LTS:0DRV with a GF Score™ of 74/100 and a GF Value™ of kr25.91 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 369 Biotechnology companies, ArcticZymes Technologies ASA ranks worse than 86.45% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ArcticZymes Technologies ASA's Enterprise Value for the quarter that ended in Jun. 2026 was kr816.8 Mil.
ArcticZymes Technologies ASA's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr11.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArcticZymes Technologies ASA EV-to-EBIT Related Terms
ArcticZymes Technologies ASA EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRV vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's EV-to-EBIT falls into.
ArcticZymes Technologies ASA's current Enterprise Value is kr776.0 Mil.
ArcticZymes Technologies ASA's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr11.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArcticZymes Technologies ASA (LTS:0DRV) has a EV-to-EBIT of 67.03 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ArcticZymes Technologies ASA and its competitors. This is 27% above median its historical median of 52.64. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #319 out of 369 companies in the Biotechnology industry, placing it in the top 86.4%.
Is ArcticZymes Technologies ASA's EV-to-EBIT too high?
ArcticZymes Technologies ASA's current EV-to-EBIT of 67.03 is 27% above median its 10-year median of 52.64. The Biotechnology industry median EV-to-EBIT is 15.95. ArcticZymes Technologies ASA's value of 67.03 is 320.3% above this industry median. Based on the distribution chart, ArcticZymes Technologies ASA ranks #319 out of 369 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #319 out of 369 companies for EV-to-EBIT. This places ArcticZymes Technologies ASA in the lower half of its industry. The industry median EV-to-EBIT is 15.95. ArcticZymes Technologies ASA's value of 67.03 is 320.3% above this benchmark. While the company's 10-year median is 52.64 vs. the industry median of 15.95, ArcticZymes Technologies ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ArcticZymes Technologies ASA's current EV-to-EBIT of 67.03 is 320.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ArcticZymes Technologies ASA and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArcticZymes Technologies ASA's current EV-to-EBIT is 67.03, which is 27% above median its own 10-year median of 52.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.91, compared to a current price of kr20.30 — trading 21.7% below its estimated fair value. The current EV-to-EBIT is 67.03, which is 27% above median its 10-year median of 52.64 and 320.3% above the Biotechnology industry median of 15.95. ArcticZymes Technologies ASA's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current EV-to-EBIT is 67.03 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr20.30 is trading 21.7% below its estimated GF Value™ of kr25.91.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
EV-to-EBIT: 67.03 (27% above median its 10-year median of 52.64)
GF Value™: kr25.91 vs. price of kr20.30 (21.7% below fair value)
Industry Position: 320.3% above the Biotechnology median (#319 of 369)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
74GF Score
Get the complete analysis for LTS:0DRV
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
